Cystic echinococcosis Infections and Infestations
Conditions
Interventions
A discontinuous treatment: 30 days treatment with a 15-day break between two 7-day courses of the corresponding drug was basically used in all patients from the beginning until the end of the study.
ABZ had to be suspended until all the abnormal values disappeared. Only then, ABZ delivery was resumed at 7.5 mg/kg/day, associated with PZQ at a dosage of 40 mg/kg/day, allowing the follow-up to cont
Sponsors
University of the Republic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients were recruited from January 2003 to October 2020 from different hospitals throughout Uruguay who completed the 5 years post-treatment follow-up in October 2020 2. Patients with cystic echinococcosis diagnosis, based on clinical symptoms, morphological features detected by imaging techniques (RX, US, CT, MR) and immunologic tests (indirect hemagglutination [IHA], indirect immunofluorescence [IFI]) 3. Less or equal cysts size to 7 cm, remnants post-surgical act, high surgical risk or multiple locations 4. Stage CE1, CE2 o CE3a o CE3b
Exclusion criteria
Exclusion criteria: 1. Patients who did not fulfil the follow-up criteria 2. Surgical treatment: Patients with low or moderate surgical risk and cysts larger than 7 cm, were subjected to surgery. However, the protocols require mandatory surgery for any cysts with a pulmonary location.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Size of the cyst measured by computed tomography (CT) or nuclear magnetic resonance (NMR) at 5 years of follow-up | — |
Secondary
| Measure | Time frame |
|---|---|
| Stage of the cyst measured by computed tomography (CT) or magnetic resonance imaging (MRI) from active (CE1, CE2) to inactive (CE4 and CE5) stages during medical treatment at 5-year follow-up | — |
Countries
Uruguay
Outcome results
None listed